AI Engine for Drug Discovery Using Generative Adversarial Networks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug discovery techniques are inefficient, limited in application, and often result in ineffective or dangerous drugs, particularly for diseases like prosthetic joint infections, due to constrained design spaces and inability to handle complex biological data effectively.
Innovation Solution
An artificial intelligence engine that uses machine learning models, including generative adversarial networks and causal inference, to expand the drug design space by incorporating structural, physical, semantic, and activity information, enabling the generation of candidate drug compounds with desired properties through a biological context representation and optimization processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional drug discovery techniques are used, then the process is simple and well-established, but the design space is constrained and productivity is low
Solution Approach 1:
The patent replaces conventional mechanical and chemical drug discovery methods with an artificial intelligence system that uses machine learning models, generative adversarial networks, and causal inference algorithms to generate and evaluate candidate drug compounds, thereby dramatically improving productivity while managing complexity through computational abstraction
Solution Approach 2:
The patent creates a composite AI system that integrates multiple different machine learning models (generative adversarial networks, causal inference models, structure-activity relationship models) into a unified drug discovery platform, combining the strengths of each model type to achieve superior drug candidate generation and evaluation
2Manufacturing precision
If conventional drug discovery methods are used, then resource consumption is manageable, but manufacturing precision and drug effectiveness are insufficient
Solution Approach 1:
The patent performs preliminary computational screening and evaluation of vast numbers of candidate drug compounds using AI models before physical synthesis and testing, allowing for high-precision identification of promising candidates while reducing the quantity of physical resources needed for actual drug development
Solution Approach 2:
The patent creates computational representations and models of drug compounds and their biological interactions, using virtual simulations and predictive algorithms to evaluate drug candidates in silico before physical experimentation, thereby achieving high manufacturing precision with reduced material consumption
3Adaptability or versatility
If conventional techniques are used, then the approach is straightforward, but adaptability to complex biological data is poor
Solution Approach 1:
The patent develops a universal AI platform that can handle multiple types of complex biological data (genomic, proteomic, metabolomic, clinical data) and apply different machine learning models to various drug discovery tasks, providing adaptability across diverse biological contexts while managing system complexity through modular architecture
4Reliability
If conventional drug discovery is used, then the process is fast and simple, but reliability and drug safety are compromised
Solution Approach 1:
The patent implements feedback mechanisms where AI models continuously learn from experimental results and computational predictions, refining their algorithms to improve drug candidate quality and safety assessments, thereby increasing reliability while maintaining efficient discovery timelines through iterative optimization
Data Source
AI summary
In one aspect, a method for pre-clinical validation of an effectiveness of a candidate drug compound is disclosed. The method may include receiving, at a processing device, a signal that comprises at least two wavelengths that are each associated with a respective biomarker, wherein the signal is received subsequent to administering the candidate drug compound to a proxy organism, such organism including at least two assays configured to reveal the respective biomarkers. The method also may include analyzing the signal to obtain the at least two wavelengths, and detecting, based on an analysis of the at least two wavelengths, whether each of the respective biomarkers are present.